In this study, we presented strong evidence that such a replication-defective ΔM062R MYXV can enhance immunotherapy for OC and alleviate ovarian TAM immunosuppression of DC-stimulated tumor antigen-specific human CD4+ T cell responses. This evidence concerns the gene CD4 and neoplasm.